Table 2.
Class | Medication | Typical Dose and Route | Estimation of Efficacya |
---|---|---|---|
Dopamine receptor antagonist | |||
Chlorpromazine | 0.1 mg/kg to 25 mg IV or IM |
|
|
Prochlorperazine | 10 mg IV or IM; 25 mg PR | ||
Promethazine | 25 mg IM (caution with IV administration) | NA | |
Metoclopramide | 10 mg IV | ||
Serotonin (5-HT1B/1D) receptor agonists: triptansb | |||
Sumatriptan | 6 mg SC | ||
10 or 20 mg intranasal | |||
Ergot derivatives | |||
Dihydroergotamine | 0.5 to 1 mg IM or IV | ||
NSAIDsb | |||
Ketorolac | 30 mg IM or IV | ||
Diclofenac | 75 mg IM |
|
|
Antiepileptics | Sodium valproate | 300-1200 mg IV |
Abbreviations: IM, intramuscular; IV, intravenous; NSAIDs, nonsteroidal anti-inflammatory drugs; PR, per rectum.
a See the corresponding section in the text for a more complete description of each agent’s efficacy in trials. Due to the heterogeneity in the trials’ primary end points, direct comparison of efficacy between agents within this table is not possible. Only trials performed in an emergency room setting were included in this table.
b Triptans and NSAIDs can be combined for improved efficacy53 in treating acute migraine, though this has not been specifically studied in the emergency department setting.